Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway

J Ethnopharmacol. 2021 Dec 5:281:114558. doi: 10.1016/j.jep.2021.114558. Epub 2021 Aug 24.

Abstract

Ethnopharmacological relevance: Radix Astragali, the dried root of Astragalus mongholicus Bunge, has long been used in traditional Chinese Medicine to treat diabetes. Astragaloside IV (AS-IV), one of the most active ingredients in the root, has been shown to have anti-diabetes ability; however, its underlying mechanism is still unclear.

Materials and methods: In this study, we evaluated the hypoglycemic effect and possible mechanisms of AS-IV in diabetic mice and insulin resistance-HepG2 cells. The components of the intestinal microflora in mice with type 2 diabetes mellitus (T2DM) were determined using high-throughput 16S rRNA gene sequencing. Moreover, the molecular mechanisms of specific members of insulin signaling pathways were analyzed.

Results: AS-IV significantly reversed the abnormalities in blood lipids, glucose, insulin resistance, as well as oxidative stress levels in T2DM mice. Histological finding showed that AS-IV could protect the cellular architecture of the liver and pancreas. AS-IV also regulated the abundance and diversity of intestinal flora of T2DM mice in a positive direction and increased butyric acid levels. The active role of AS-IV as an anti-diabetic compound by regulating the AMPK/SIRT1 and PI3K/AKT signaling pathways was revealed using a T2DM model and verified through the intervention of inhibitors using insulin-resistance HepG2 cells.

Conclusion: Our results suggested that AS-IV may be used as an anti-diabetic drug candidate owing to its effects of regulating gut microbiota and AMPK/SIRT1 and PI3K/AKT signaling pathways.

Keywords: AMPK/SIRT1 and PI3K/AKT signaling pathways; Astragaloside IV; Gut microbiota; Insulin resistance; T2DM.

MeSH terms

  • Adenylate Kinase / genetics
  • Adenylate Kinase / metabolism*
  • Animals
  • Blood Glucose / drug effects
  • Diabetes Mellitus, Experimental / drug therapy
  • Diet, High-Fat / adverse effects
  • Dietary Sucrose / adverse effects
  • Gastrointestinal Microbiome / drug effects*
  • Gene Expression Regulation / drug effects
  • Glucose / metabolism
  • Hep G2 Cells
  • Humans
  • Hypoglycemic Agents / chemistry
  • Hypoglycemic Agents / pharmacology
  • Insulin / blood
  • Male
  • Phosphatidylinositol 3-Kinases / genetics
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Proto-Oncogene Proteins c-akt / genetics
  • Proto-Oncogene Proteins c-akt / metabolism*
  • Saponins / pharmacology*
  • Sirtuin 1 / genetics
  • Sirtuin 1 / metabolism*
  • Specific Pathogen-Free Organisms
  • Triterpenes / pharmacology*

Substances

  • Blood Glucose
  • Dietary Sucrose
  • Hypoglycemic Agents
  • Insulin
  • Saponins
  • Triterpenes
  • astragaloside A
  • Proto-Oncogene Proteins c-akt
  • Adenylate Kinase
  • Sirt1 protein, mouse
  • Sirtuin 1
  • Glucose